Last reviewed · How we verify
Aspirin and thienopyridine
Aspirin and thienopyridine is a Dual antiplatelet agent combination Small molecule drug developed by Associations for Establishment of Evidence in Interventions. It is currently FDA-approved for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of myocardial infarction and stent thrombosis, Stroke prevention in patients with recent ischemic stroke or transient ischemic attack.
Aspirin and thienopyridine work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.
Aspirin and thienopyridine work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of myocardial infarction and stent thrombosis, Stroke prevention in patients with recent ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Aspirin and thienopyridine |
|---|---|
| Sponsor | Associations for Establishment of Evidence in Interventions |
| Drug class | Dual antiplatelet agent combination |
| Target | COX-1 (aspirin); P2Y12 receptor (thienopyridine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Thienopyridines (such as clopidogrel or ticlopidine) are P2Y12 adenosine diphosphate receptor antagonists that block platelet aggregation. Together, they provide complementary antiplatelet effects, reducing thrombotic events more effectively than either agent alone.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of myocardial infarction and stent thrombosis
- Stroke prevention in patients with recent ischemic stroke or transient ischemic attack
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Neutropenia (thienopyridine-specific)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin and thienopyridine CI brief — competitive landscape report
- Aspirin and thienopyridine updates RSS · CI watch RSS
- Associations for Establishment of Evidence in Interventions portfolio CI
Frequently asked questions about Aspirin and thienopyridine
What is Aspirin and thienopyridine?
How does Aspirin and thienopyridine work?
What is Aspirin and thienopyridine used for?
Who makes Aspirin and thienopyridine?
What drug class is Aspirin and thienopyridine in?
What development phase is Aspirin and thienopyridine in?
What are the side effects of Aspirin and thienopyridine?
What does Aspirin and thienopyridine target?
Related
- Drug class: All Dual antiplatelet agent combination drugs
- Target: All drugs targeting COX-1 (aspirin); P2Y12 receptor (thienopyridine)
- Manufacturer: Associations for Establishment of Evidence in Interventions — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Indication: Drugs for Secondary prevention of myocardial infarction and stent thrombosis
- Indication: Drugs for Stroke prevention in patients with recent ischemic stroke or transient ischemic attack
- Compare: Aspirin and thienopyridine vs similar drugs
- Pricing: Aspirin and thienopyridine cost, discount & access